76417-04-4

Basic information

• Product Name: virantmycin
• Synonyms: virantmycin
• CAS NO: 76417-04-4
• Molecular Formula: C₁₉H₂₆ClNO₃
• Molecular Weight: 351.871
• Mol File: 76417-04-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: virantmycin(CAS DataBase Reference)
• NIST Chemistry Reference: virantmycin(76417-04-4)
• EPA Substance Registry System: virantmycin(76417-04-4)

Safety Data

• Hazardous Substances Data: 76417-04-4(Hazardous Substances Data)

Usage

Description

Virantmycin is a macrolide antibiotic compound that is effective in treating a variety of bacterial infections by inhibiting bacterial growth and reproduction, thereby supporting the body's immune system in combating the infection.

Uses

Used in Medical Applications:
Virantmycin is used as an antibiotic for treating a range of bacterial infections, including skin and soft tissue infections, pneumonia, and sexually transmitted diseases. Its broad-spectrum activity allows it to target a wide range of bacteria, making it a versatile treatment option.
Used in Pharmaceutical Industry:
Virantmycin is used as a pharmaceutical agent for its broad-spectrum antibacterial properties, commonly administered orally or through intravenous injection. It is valued for its effectiveness in treating various infections and for being generally well-tolerated, although it may cause side effects in some individuals such as nausea, vomiting, diarrhea, or allergic reactions.

Upstream product

• 201230-82-2 carbon monoxide 
• 586390-86-5 (2R,3R)-3-chloro-2-(3,4-dimethylpent-3-enyl)-6-iodo-2-methoxymethyl-1,2,3,4-tetrahydroquinoline 
• 19718-49-1 4-amino-3-iodobenzoic acid methyl ester 
• 104784-27-2 methyl N-formyl-2-(3,4-dimethylpent-3-enyl)-3-hydroxy-2-(methoxymethyl)-1,2,3,4-tetrahydroquinoline-6-carboxylate 
• 104784-25-0 methyl N-formyl-2-(3,4-dimethyl-3,4-epoxypentyl)-3-hydroxy-2-(methoxymethyl)-1,2,3,4-tetrahydroquinoline-6-carboxylate 
• 104784-22-7 methyl N-formyl-2-(3,4-dimethyl-3,4-epoxypentyl)-3,4-epoxy-2-(methoxymethyl)-1,2,3,4-tetrahydroquinoline-6-carboxylate 
• 5072-70-8 1-bromo-2,3-dimethyl-2-butene 
• 619-45-4 4-methoxycarbonyl aniline 
• 104784-24-9 methyl N-formyl-1,2-dihydro-2-(3,4-dimethylpent-3-enyl)-2-(methoxymethyl)quinoline-6-carboxylate 
• 104784-21-6 methyl 3-(6,7-dimethyl-3-hydroxy-3-methoxymethyloct-6-en-1-ynyl)-4-aminobenzoate 
• 104784-26-1 methyl 2-(3,4-dimethylpent-3-enyl)-3-hydroxy-2-(methoxymethyl)-1,2,3,4-tetrahydroquinoline-6-carboxylate 
• 104784-23-8 2-(3,4-Dimethyl-pent-3-enyl)-2-methoxymethyl-1,2-dihydro-quinoline-6-carboxylic acid methyl ester 
• 104784-20-5 2-(2-Methoxy-acetyl)-4,5-dimethyl-hex-4-enoic acid methyl ester 
• 104784-19-2 6,7-dimethyl-3-methoxymethyloct-6-en-1-yn-3-ol 

Relevant articles and documents

Stereospecific construction of contiguous quaternary and tertiary stereocenters by rearrangement from indoline-2-methanol to 2,2,3-trisubstituted tetrahydroquinoline: Application to an efficient total synthesis of natural virantmycin

Only nine steps away: PPh3/CCl4-mediated stereospecific rearrangement of α,α-disubstituted indoline-2-methanol to 2,2,3-trisubstituted optically active tetrahydroquinoline (see scheme) has been developed. The reaction was applied to

A simple convergent approach to the synthesis of the antiviral agent virantmycin

Formula presented The antiviral agent (±)-virantmycin has been synthesized from two simple building blocks (2 and 3) in eight steps, as outlined in Scheme 2.

TOTAL SYNTHESIS OF THE ANTIVIRAL (+/-)-VIRANTMYCIN

The total synthesis of the racemic modification of the antiviral metabolite virantmycin is described starting from p-aminobenzoic acid and utilising acetylenic precursors.